Substituted quinazolinones bearing acidic functional groups as angiotensin II antagonists
First Claim
Patent Images
1. A compound of formula (I):
- ##STR154## or a pharmaceutically acceptable salt thereof, wherein;
L is connected with J or K to form an aromatic ring as defined below;
J and L are connected together to form a 6 carbon aromatic ring substituted with R7a, R7b, R8a and R8b ;
K is --C(═
O)--;
R1 is --SO2 NHCO2 R23 ;
R2a and R2b are each independently(a) H,(b) halogen, (Cl, Br, I, F),(c) NO2,(d) NH2,(e) C1 -C4 -alkylamino,(f) di(C1 -C4 -alkyl)amino,(g) SO2 NHR9,(h) CF3,(i) C1 -C6 -alkyl,(j) C1 -C6 -alkoxy,(k) (C1 -C6 -alkoxy)--CH2 --,(l) (C1 -C6 -alkyl-S)--CH2 --,(m) C1 -C6 -alkyl--S--,(n) --CH2 NR9 R9,(o) C2 -C6 -alkenyl,(p) C2 -C6 -alkynyl;
(q) aryl as defined below,(r) aryl(C1 -C4 -alkyl), or(s) C3 -C7 -cycloalkyl;
R3a is(a) H,(b) halogen (Cl, Br, I, F),(c) C1 -C6 -alkyl,(d) C1 -C6 -alkoxy, or(e) C1 -C6 -alkoxyalkyl;
R3b is(a) H,(b) halogen (Cl, Br, I, F),(c) NO2,(d) C1 -C6 -alkyl,(e) C1 -C6 -acyloxy, or(f) C3 -C7 -cycloalkyl,(g) C1 -C6 -alkoxy,(h) --NHSO2 R4,(i) hydroxy(C1 -C4 -alkyl),(j) aryl(C1 -C4 -alkyl),(k) C1 -C4 -alkylthio,(l) C1 -C4 -alkyl sulfinyl,(m) C1 -C4 -alkyl sulfonyl,(n) NH2,(o) C1 -C4 -alkylamino,(p) di(C1 -C4 -alkyl)amino,(q) fluoro-C1 -C4 -alkyl-,(r) --SO2 --NHR9,(s) aryl as defined below,(t) furyl,(u) CF3,(v) C2 -C6 -alkenyl, or(w) C2 -C6 -alkynyl;
wherein aryl is phenyl or naphthyl optionally substituted with one or two substituents selected from the group consisting of halogen(Cl, Br, I, F), N(R4)2, CO2 R4, C1 -C4 -alkyl, C1 -C4 -alkoxy, NO2, CF3, C1 -C4 -alkylthio, OH, --SO2 NR9 R10, C3 -C7 -cycloalkyl, C3 -C10 -alkenyl, and --S(O)x (C1 -C4 -alkyl);
R4 is H, aryl as defined above, straight chain or branched C1 -C6 alkyl optionally substituted with aryl as defined above, or heteroaryl, wherein heteroaryl is an unsubstituted, monosubstituted or disubstituted heteroaromatic 5 or 6 membered ring which can contain one or two heteroatoms selected from the group consisting of N, O, and S, and wherein the substituents are members selected from the group consisting of --OH, --SH, C1 -C4 -alkyl, C1 -C4 -alkoxy, --CF3, halogen (Cl, Br, I, F), and NO2 ;
R4a is aryl as defined above, C1 -C6 -alkyl, or aryl-C1 -C6 -alkylR5 is H, ##STR155## E is a single bond, --NR13 (CH2)s --, --S(O)x (CH2)s -- where x is 0 to 2 and s is 0 to 5, --CH(OH)--, --O--, or CO--;
R6 is(a) aryl,(b) straight chain or branched C1 -C6 -alkyl, C2 -C5 -alkenyl or C2 -C5 -alkynyl each of which can be optionally substituted with a substituent selected from the group consisting of aryl as defined above, C3 -C7 -cycloalkyl, halogen (Cl, Br, I, F), CF3, CF2 CF3, --NH2, --NH(C1 -C4 -alkyl), --OR4 --N(C1 -C4 -alkyl)2, --NH--SO2 R4, --COOR4, and --SO2 NHR9,(c) heteroaryl as defined hereinabove,(d) C3 -C7 -cycloalkyl,(e) perfluoro-C1 -C4 -alkyl, or(f) H;
R7a and R7b are independently(a) H,(b) straight chain or branched C1 -C6 -alkyl, C2 -C6 -alkenyl or C2 -C6 -alkynyl,(c) halogen (Cl, Br, I, F),(d) CF3, or(e) when R7a and R7b are bonded to adjacent carbon atoms, they can be joined to form a phenyl ring;
R8a and R8b are independently(a) H,(b) C1 -C6 -alkyl optionally substituted with a substituent selected from the group consisting of --OH, -guanidino, C1 -C4 -alkoxy, --N(R4)2, COOR4, --CON(R4)2, --O--COR4, -aryl, -heteroaryl, --S(O)x --R23, -tetrazol-5-yl, --CONHSO2 R23, --SO2 NH-heteroaryl, --SO2 NHCOR23, --PO(OR4)2, --PO(OR4)R9, --SO2 NH--CN, --NR10 COOR23, morpholino, --N--(C1 -C6 -alkyl)piperazine, --COR4, ##STR156## (c) --CO-aryl, (d) --C3 -C7 -cycloalkyl,(e) halogen (Cl, Br, I, F),(f) --OH,(g) --OR23,(h) --C1 -C4 -perfluoroalkyl,(i) --S(O)x --R23,(j) --COOR4,(k) --SO3 H,(l) --NR4 R23,(m) --NR24 COR23,(n) --NR24 COOR23,(o) --SO2 NR9 R10,(p) --NO2,(q) --NR24 SO2 R23,(r) --NR24 CONR4 R23,(s) ##STR157## (t) -aryl or -heteroaryl as defined above, (u) --NR24 SO2 CF3,(v) --SO2 NH-heteroaryl,(w) --SO2 NHCOR23,(x) --CONHSO2 R23,(y) --PO(OR4)2,(z) --PO(OR4)R9,(aa) -tetrazol-5-yl,(bb) --CONH(tetrazol-5-yl),(cc) --COR4,(dd) --SO2 NHCN(ff) --CO-heteroraryl,(gg) --NR24 SO2 NR23 R9,(hh) ##STR158## (ii) ##STR159## (jj) ##STR160## (kk) ##STR161## (ll) ##STR162## (mm) ##STR163## (nn) ##STR164## or (oo) ##STR165## R9 is H, C1 -C5 -alkyl, aryl or arylmethyl;
R10 is H, C1 -C4 -alkyl;
R11 is H, C1 -C6 -alkyl, C1 -C4 -alkenyl, C1 -C4 -alkoxy alkyl, or ##STR166## R12 is --CN, --NO2, --CF3 or --CO2 R4 ;
R13 is H, (C1 -C4 -alkyl)CO--, C1 -C6 -alkyl, allyl, C3 -C6 -cycloalkyl, aryl or arylmethyl;
R14 is H, C1 -C8 -alkyl, C1 -C8 -perfluoroalkyl, C3 -C6 -cycloalkyl, aryl or arylmethyl;
R15 is H, C1 -C6 -alkyl;
R16 is H, C1 -C6 -alkyl, C3 -C6 -cycloalkyl, aryl or arylmethyl;
R17 is --NR9 R10, --OR10, --NHCONH2, --NHCSNH2, ##STR167## R18 and R19 are independently C1 -C4 -alkyl or taken together are --(CH2)q - where q is 2 or 3;
R20 is H, --NO2, --NH2, --OH or --OCH3 ;
R21 is H, aryl, or C1 -C4 -alkyl optionally substituted with aryl, --NH2, --NH(C1 -C4 -alkyl), --N(C1 -C4 -alkyl)2, --CO2 R4, --OH, --SO3 H, or --SO2 NH2 ;
R22 is(a) aryl as defined above,(b) heteroaryl as defined above, or(c) C1 -C4 -alkyl optionally substituted with a substituent selected from the group consisting of aryl as defined above, heteroaryl as defined above, --OH, --NH2, --NH(C1 -C4 -alkyl), --N(C1 -C4 -alkyl)2, --CO2 R4, halogen (Cl, Br, F, I), and --CF3 ;
R23 is(a) aryl as defined above,(b) heteroaryl as defined above,(c) C3 -C7 -cycloalkyl,(d) C1 -C6 -alkyl optionally substituted with a substituent selected from the group consisting of aryl as defined above, heteroaryl as defined above, --OH, --SH, C1 -C4 -alkyl, --O(C1 -C4 -alkyl), C3 -C7 -cycloalkyl, --S(O)x (C1 -C4 -alkyl), --CF3, halogen (Cl, Br, F, I), --NO2, --CO2 H, CO2 --C1 -C4 -alkyl, --NH2, --NH(C1 -C4 -alkyl), --N(C1 -C4 -alkyl)2, --PO3 H2, --PO(OH)(O--C1 -C4 -alkyl), --N(C1 -C4 -alkyl)COR4a, --CON(C1 -C4 -alkyl)2, or --PO(OR4)R9,(e) perfluoro-C1 -C4 -alkyl, or(f) CH(aryl)2 ;
R24 is(a) C1 -C6 alkyl,(b) substituted C1 -C6 alkyl in which the substituent is C3 -C7 cycloalkyl, C1 -C4 alkoxy, hydroxy, di-(C1 -C4 alkyl)amino, CO2 R2, morpholinyl, C1 -C4 alkylpiperazinyl, CF3, C1 -C4 alkylthio, C1 -C4 alkylsulfinyl or C1 -C4 alkyl sulfonyl,(c) C2 -C6 alkenyl,(d) phenyl C1 -C6 alkyl,(e) substituted phenyl C1 -C6 alkyl, in which the substituent on the phenyl group is hydroxy, C1 -C4 alkoxy, F, Cl, NO2, cyano, CO2 R2, di(C1 -C4 alkyl)amino, CF3, phenyl C1 -C4 alkoxy, C1 -C4 alkylthio, C1 -C4 alkylsulfinyl, or C1 -C4 alkylsulfonyl,(f) heteroaryl C1 -C6 alkyl,(g) substituted heteroaryl C1 -C6 alkyl, in which the substituent on the heteroaryl group is F, Cl, NO2, CO2 R2, or di-(C1 -C4 alkyl)amino, and(h) H;
R25 is(a) H,(b) aryl as defined above, or(c) C1 -C6 -alkyl optionally substituted with aryl, F, Cl, Br, --OH, --NH2, --NH(C1 -C4 -alkyl), --N(C1 -C4 -alkyl)2, or CF3 ;
R26 is(a) aryl as defined above,(b) C1 -C6 -alkyl optionally substituted with aryl, F, Cl, Br, --OH, --NH2, --NH(C1 -C4 -alkyl), --N(C1 -C4 -alkyl)2, CF3, --COOR4, or CN,(c) --OCH(R4)--O--CO--R4a, or(d) --OH or --O--C1 -C6 -alkyl wherein alkyl is as defined in (b);
R27 is(a) H,(b) C1 -C6 -alkyl optionally substituted with aryl, F, Cl, Br, --OH, --NH2, --NH(C1 -C4 -alkyl), --N(C1 -C4 -alkyl)2, CF3, --COOR4, or CN, or(c) F, Cl, Br;
X is(a) a carbon-carbon single bond,(b) --CO--,(c) --O--,(d) --S--,(e) ##STR168## (f) ##STR169## (g) ##STR170## (h) --OCH2 --, (i) --CH2 O--,(j) --SCH2 --,(k) --CH2 S--,(l) --NHC(R9)(R10),(m) --NR9 SO2 --,(n) --SO2 NR9 --,(o) --C(R9)(R10)NH--,(p) --CH═
CH--,(q) --CF═
CF--,(r) --CH═
CF--,(s) --CF═
CH--,(t) --CH2 CH2 --,(u) --CF2 CF2 --,(v) ##STR171## (w) ##STR172## (x) ##STR173## (y) ##STR174## or (z) ##STR175## n is 1 to 3;
r is 1 or 2; and
x is 0 to 2.
1 Assignment
0 Petitions
Accused Products
Abstract
Novel substituted quinazolinones of the formula (I) are useful as angiotensin II antagonists. ##STR1##
36 Citations
9 Claims
-
1. A compound of formula (I):
- ##STR154## or a pharmaceutically acceptable salt thereof, wherein;
L is connected with J or K to form an aromatic ring as defined below;J and L are connected together to form a 6 carbon aromatic ring substituted with R7a, R7b, R8a and R8b ; K is --C(═
O)--;R1 is --SO2 NHCO2 R23 ; R2a and R2b are each independently (a) H, (b) halogen, (Cl, Br, I, F), (c) NO2, (d) NH2, (e) C1 -C4 -alkylamino, (f) di(C1 -C4 -alkyl)amino, (g) SO2 NHR9, (h) CF3, (i) C1 -C6 -alkyl, (j) C1 -C6 -alkoxy, (k) (C1 -C6 -alkoxy)--CH2 --, (l) (C1 -C6 -alkyl-S)--CH2 --, (m) C1 -C6 -alkyl--S--, (n) --CH2 NR9 R9, (o) C2 -C6 -alkenyl, (p) C2 -C6 -alkynyl; (q) aryl as defined below, (r) aryl(C1 -C4 -alkyl), or (s) C3 -C7 -cycloalkyl; R3a is (a) H, (b) halogen (Cl, Br, I, F), (c) C1 -C6 -alkyl, (d) C1 -C6 -alkoxy, or (e) C1 -C6 -alkoxyalkyl; R3b is (a) H, (b) halogen (Cl, Br, I, F), (c) NO2, (d) C1 -C6 -alkyl, (e) C1 -C6 -acyloxy, or (f) C3 -C7 -cycloalkyl, (g) C1 -C6 -alkoxy, (h) --NHSO2 R4, (i) hydroxy(C1 -C4 -alkyl), (j) aryl(C1 -C4 -alkyl), (k) C1 -C4 -alkylthio, (l) C1 -C4 -alkyl sulfinyl, (m) C1 -C4 -alkyl sulfonyl, (n) NH2, (o) C1 -C4 -alkylamino, (p) di(C1 -C4 -alkyl)amino, (q) fluoro-C1 -C4 -alkyl-, (r) --SO2 --NHR9, (s) aryl as defined below, (t) furyl, (u) CF3, (v) C2 -C6 -alkenyl, or (w) C2 -C6 -alkynyl; wherein aryl is phenyl or naphthyl optionally substituted with one or two substituents selected from the group consisting of halogen(Cl, Br, I, F), N(R4)2, CO2 R4, C1 -C4 -alkyl, C1 -C4 -alkoxy, NO2, CF3, C1 -C4 -alkylthio, OH, --SO2 NR9 R10, C3 -C7 -cycloalkyl, C3 -C10 -alkenyl, and --S(O)x (C1 -C4 -alkyl); R4 is H, aryl as defined above, straight chain or branched C1 -C6 alkyl optionally substituted with aryl as defined above, or heteroaryl, wherein heteroaryl is an unsubstituted, monosubstituted or disubstituted heteroaromatic 5 or 6 membered ring which can contain one or two heteroatoms selected from the group consisting of N, O, and S, and wherein the substituents are members selected from the group consisting of --OH, --SH, C1 -C4 -alkyl, C1 -C4 -alkoxy, --CF3, halogen (Cl, Br, I, F), and NO2 ; R4a is aryl as defined above, C1 -C6 -alkyl, or aryl-C1 -C6 -alkyl R5 is H, ##STR155## E is a single bond, --NR13 (CH2)s --, --S(O)x (CH2)s -- where x is 0 to 2 and s is 0 to 5, --CH(OH)--, --O--, or CO--; R6 is (a) aryl, (b) straight chain or branched C1 -C6 -alkyl, C2 -C5 -alkenyl or C2 -C5 -alkynyl each of which can be optionally substituted with a substituent selected from the group consisting of aryl as defined above, C3 -C7 -cycloalkyl, halogen (Cl, Br, I, F), CF3, CF2 CF3, --NH2, --NH(C1 -C4 -alkyl), --OR4 --N(C1 -C4 -alkyl)2, --NH--SO2 R4, --COOR4, and --SO2 NHR9, (c) heteroaryl as defined hereinabove, (d) C3 -C7 -cycloalkyl, (e) perfluoro-C1 -C4 -alkyl, or (f) H; R7a and R7b are independently (a) H, (b) straight chain or branched C1 -C6 -alkyl, C2 -C6 -alkenyl or C2 -C6 -alkynyl, (c) halogen (Cl, Br, I, F), (d) CF3, or (e) when R7a and R7b are bonded to adjacent carbon atoms, they can be joined to form a phenyl ring; R8a and R8b are independently (a) H, (b) C1 -C6 -alkyl optionally substituted with a substituent selected from the group consisting of --OH, -guanidino, C1 -C4 -alkoxy, --N(R4)2, COOR4, --CON(R4)2, --O--COR4, -aryl, -heteroaryl, --S(O)x --R23, -tetrazol-5-yl, --CONHSO2 R23, --SO2 NH-heteroaryl, --SO2 NHCOR23, --PO(OR4)2, --PO(OR4)R9, --SO2 NH--CN, --NR10 COOR23, morpholino, --N--(C1 -C6 -alkyl)piperazine, --COR4, ##STR156## (c) --CO-aryl, (d) --C3 -C7 -cycloalkyl, (e) halogen (Cl, Br, I, F), (f) --OH, (g) --OR23, (h) --C1 -C4 -perfluoroalkyl, (i) --S(O)x --R23, (j) --COOR4, (k) --SO3 H, (l) --NR4 R23, (m) --NR24 COR23, (n) --NR24 COOR23, (o) --SO2 NR9 R10, (p) --NO2, (q) --NR24 SO2 R23, (r) --NR24 CONR4 R23, (s) ##STR157## (t) -aryl or -heteroaryl as defined above, (u) --NR24 SO2 CF3, (v) --SO2 NH-heteroaryl, (w) --SO2 NHCOR23, (x) --CONHSO2 R23, (y) --PO(OR4)2, (z) --PO(OR4)R9, (aa) -tetrazol-5-yl, (bb) --CONH(tetrazol-5-yl), (cc) --COR4, (dd) --SO2 NHCN (ff) --CO-heteroraryl, (gg) --NR24 SO2 NR23 R9, (hh) ##STR158## (ii) ##STR159## (jj) ##STR160## (kk) ##STR161## (ll) ##STR162## (mm) ##STR163## (nn) ##STR164## or (oo) ##STR165## R9 is H, C1 -C5 -alkyl, aryl or arylmethyl;
R10 is H, C1 -C4 -alkyl;R11 is H, C1 -C6 -alkyl, C1 -C4 -alkenyl, C1 -C4 -alkoxy alkyl, or ##STR166## R12 is --CN, --NO2, --CF3 or --CO2 R4 ;
R13 is H, (C1 -C4 -alkyl)CO--, C1 -C6 -alkyl, allyl, C3 -C6 -cycloalkyl, aryl or arylmethyl;R14 is H, C1 -C8 -alkyl, C1 -C8 -perfluoroalkyl, C3 -C6 -cycloalkyl, aryl or arylmethyl; R15 is H, C1 -C6 -alkyl; R16 is H, C1 -C6 -alkyl, C3 -C6 -cycloalkyl, aryl or arylmethyl; R17 is --NR9 R10, --OR10, --NHCONH2, --NHCSNH2, ##STR167## R18 and R19 are independently C1 -C4 -alkyl or taken together are --(CH2)q - where q is 2 or 3; R20 is H, --NO2, --NH2, --OH or --OCH3 ; R21 is H, aryl, or C1 -C4 -alkyl optionally substituted with aryl, --NH2, --NH(C1 -C4 -alkyl), --N(C1 -C4 -alkyl)2, --CO2 R4, --OH, --SO3 H, or --SO2 NH2 ; R22 is (a) aryl as defined above, (b) heteroaryl as defined above, or (c) C1 -C4 -alkyl optionally substituted with a substituent selected from the group consisting of aryl as defined above, heteroaryl as defined above, --OH, --NH2, --NH(C1 -C4 -alkyl), --N(C1 -C4 -alkyl)2, --CO2 R4, halogen (Cl, Br, F, I), and --CF3 ; R23 is (a) aryl as defined above, (b) heteroaryl as defined above, (c) C3 -C7 -cycloalkyl, (d) C1 -C6 -alkyl optionally substituted with a substituent selected from the group consisting of aryl as defined above, heteroaryl as defined above, --OH, --SH, C1 -C4 -alkyl, --O(C1 -C4 -alkyl), C3 -C7 -cycloalkyl, --S(O)x (C1 -C4 -alkyl), --CF3, halogen (Cl, Br, F, I), --NO2, --CO2 H, CO2 --C1 -C4 -alkyl, --NH2, --NH(C1 -C4 -alkyl), --N(C1 -C4 -alkyl)2, --PO3 H2, --PO(OH)(O--C1 -C4 -alkyl), --N(C1 -C4 -alkyl)COR4a, --CON(C1 -C4 -alkyl)2, or --PO(OR4)R9, (e) perfluoro-C1 -C4 -alkyl, or (f) CH(aryl)2 ; R24 is (a) C1 -C6 alkyl, (b) substituted C1 -C6 alkyl in which the substituent is C3 -C7 cycloalkyl, C1 -C4 alkoxy, hydroxy, di-(C1 -C4 alkyl)amino, CO2 R2, morpholinyl, C1 -C4 alkylpiperazinyl, CF3, C1 -C4 alkylthio, C1 -C4 alkylsulfinyl or C1 -C4 alkyl sulfonyl, (c) C2 -C6 alkenyl, (d) phenyl C1 -C6 alkyl, (e) substituted phenyl C1 -C6 alkyl, in which the substituent on the phenyl group is hydroxy, C1 -C4 alkoxy, F, Cl, NO2, cyano, CO2 R2, di(C1 -C4 alkyl)amino, CF3, phenyl C1 -C4 alkoxy, C1 -C4 alkylthio, C1 -C4 alkylsulfinyl, or C1 -C4 alkylsulfonyl, (f) heteroaryl C1 -C6 alkyl, (g) substituted heteroaryl C1 -C6 alkyl, in which the substituent on the heteroaryl group is F, Cl, NO2, CO2 R2, or di-(C1 -C4 alkyl)amino, and (h) H; R25 is (a) H, (b) aryl as defined above, or (c) C1 -C6 -alkyl optionally substituted with aryl, F, Cl, Br, --OH, --NH2, --NH(C1 -C4 -alkyl), --N(C1 -C4 -alkyl)2, or CF3 ; R26 is (a) aryl as defined above, (b) C1 -C6 -alkyl optionally substituted with aryl, F, Cl, Br, --OH, --NH2, --NH(C1 -C4 -alkyl), --N(C1 -C4 -alkyl)2, CF3, --COOR4, or CN, (c) --OCH(R4)--O--CO--R4a, or (d) --OH or --O--C1 -C6 -alkyl wherein alkyl is as defined in (b); R27 is (a) H, (b) C1 -C6 -alkyl optionally substituted with aryl, F, Cl, Br, --OH, --NH2, --NH(C1 -C4 -alkyl), --N(C1 -C4 -alkyl)2, CF3, --COOR4, or CN, or (c) F, Cl, Br; X is (a) a carbon-carbon single bond, (b) --CO--, (c) --O--, (d) --S--, (e) ##STR168## (f) ##STR169## (g) ##STR170## (h) --OCH2 --, (i) --CH2 O--, (j) --SCH2 --, (k) --CH2 S--, (l) --NHC(R9)(R10), (m) --NR9 SO2 --, (n) --SO2 NR9 --, (o) --C(R9)(R10)NH--, (p) --CH═
CH--,(q) --CF═
CF--,(r) --CH═
CF--,(s) --CF═
CH--,(t) --CH2 CH2 --, (u) --CF2 CF2 --, (v) ##STR171## (w) ##STR172## (x) ##STR173## (y) ##STR174## or (z) ##STR175## n is 1 to 3;
r is 1 or 2; andx is 0 to 2. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
6. A pharmaceutical composition useful in the treatment of hypertension which comprises a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 1.
-
7. A method of treating hypertension which comprises administering to a patient in need of such treatment a pharmaceutically effective amount of a compound of claim 1.
-
8. An ophthalmological formulation for the treatment of ocular hypertension comprising an ophthalmologically acceptable carrier and an effective ocular antihypertensive amount of a compound of claim 1.
-
9. A method of treating ocular hypertension comprising administering to a patient in need of such treatment an effective ocular antihypertensive amount of a compound of claim 1.
- ##STR154## or a pharmaceutically acceptable salt thereof, wherein;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeMerck & Co., Inc.
-
Original AssigneeMerck & Co., Inc.
-
InventorsGreenlee, William J., Kim, Dooseop, Glinka, Tomasz W., Chakravarty, Prasun K., Patchett, Arthur A., Mantlo, Nathan B., de Laszlo, Stephen E.
-
Primary Examiner(s)Rizzo, Nicholas S.
-
Assistant Examiner(s)GUPTA, YOGENDRA N
-
Application NumberUS07/867,794Time in Patent Office495 DaysField of Search544/244, 544/284, 544/289, 544/293, 544/287, 544/333, 514/256, 514/269, 514/259, 514/260US Class Current514/266.2CPC Class CodesA61P 27/02 Ophthalmic agentsA61P 43/00 Drugs for specific purposes...A61P 9/12 AntihypertensivesC07D 231/12 with only hydrogen atoms, h...C07D 233/56 with only hydrogen atoms or...C07D 239/70 condensed with carbocyclic ...C07D 239/91 with aryl or aralkyl radica...C07D 249/08 1,2,4-Triazoles; Hydrogenat...C07D 401/04 directly linked by a ring-m...C07D 413/10 linked by a carbon chain co...C07D 417/10 linked by a carbon chain co...
